Court orders SIGA to pay $195,000 in case brought by PharmAthene for Tecovirimat

The Delaware Court of Chancery, USA, has entered its Final Order and Judgment in the case brought by US pharma company PharmAthene against SIGA Technologies.

The judgment against SIGA totaled $194,649,042, including $113,116,985 in lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat (ST-246), and $81,532,057 in pre-judgment interest and attorneys' and expert witness fees.

SIGA is also liable for post-judgment interest of $30,664 per day, as of January 15. The decision is subject to appeal by SIGA to the Delaware Supreme Court. PharmAthene is automatically stayed from taking any enforcement action in the Delaware Court of Chancery as SIGA has filed for protection under federal bankruptcy laws. PharmAthene’s ability to collect a money judgment from SIGA remains subject to further proceedings on the matter.